Brain-associated inhibitor of tissue-type plasminogen activator
    61.
    发明申请
    Brain-associated inhibitor of tissue-type plasminogen activator 审中-公开
    脑组织型纤溶酶原激活物抑制剂

    公开(公告)号:US20020165147A1

    公开(公告)日:2002-11-07

    申请号:US09987021

    申请日:2001-11-13

    摘要: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.

    摘要翻译: 本发明涉及一种新的BAIT蛋白,其是主要在脑组织中表达的丝氨酸蛋白酶超家族的成员。 特别地,提供了分离的核酸分子,其编码人和其制备方法。 本发明还涉及鉴定BAIT活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测神经系统相关疾病的诊断方法和用于治疗神经系统相关疾病的治疗方法。 另外,本发明涉及治疗患有BAIT多核苷酸或多肽的患者的方法,其中所述患者具有癫痫发作或癫痫。

    Pancreas-derived plasminogen activator inhibitor
    62.
    发明申请
    Pancreas-derived plasminogen activator inhibitor 失效
    胰腺来源的纤溶酶原激活物抑制剂

    公开(公告)号:US20020127640A1

    公开(公告)日:2002-09-12

    申请号:US09902684

    申请日:2001-07-12

    摘要: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions, including breast cancer, and diagnostic methods for detecting pathologic disorders.

    摘要翻译: 本发明涉及纤溶酶原激活物抑制剂蛋白家族的新成员。 特别地,提供编码胰腺衍生的纤溶酶原激活物抑制蛋白的分离的核酸分子。 还提供了胰腺来源的纤溶酶原激活物抑制剂多肽,载体,宿主细胞和用于制备它们的重组方法。 本发明还涉及用于治疗生理和病理疾病状况的方法,包括乳腺癌,以及用于检测病理障碍的诊断方法。

    Pai-1 determination and use thereof
    63.
    发明申请
    Pai-1 determination and use thereof 审中-公开
    Pai-1的确定和使用

    公开(公告)号:US20020012950A1

    公开(公告)日:2002-01-31

    申请号:US09922718

    申请日:2001-08-07

    IPC分类号: G01N033/574 G01N033/573

    摘要: A monoclonal antibody which binds a human endothelial type plasminogen activator inhibitor (PAI-1) produced by dexamethasone-treated human HT-1080 fibrosarcoma cells may be used, inter alia, for determining PAI-1 protein abundance in tumor tissue or a sample of a body fluid. Measurements of this parameter may be useful in predicting the presence or metastasis of a tumor, or of predicting the progression of a known malignant tumor.

    摘要翻译: 可以使用结合由地塞米松处理的人HT-1080纤维肉瘤细胞产生的人内皮型纤溶酶原激活物抑制剂(PAI-1)的单克隆抗体,尤其用于测定肿瘤组织中的PAI-1蛋白丰度或 体液。 该参数的测量可用于预测肿瘤的存在或转移,或预测已知恶性肿瘤的进展。

    Pancreas-derived plasminogen activator inhibitor
    64.
    发明授权
    Pancreas-derived plasminogen activator inhibitor 失效
    胰腺来源的纤溶酶原激活物抑制剂

    公开(公告)号:US06303338B1

    公开(公告)日:2001-10-16

    申请号:US09026408

    申请日:1998-02-19

    IPC分类号: C07N2100

    摘要: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions, including breast cancer, and diagnostic methods for detecting pathologic disorders.

    摘要翻译: 本发明涉及纤溶酶原激活物抑制剂蛋白家族的新成员。 特别地,提供编码胰腺衍生的纤溶酶原激活物抑制蛋白的分离的核酸分子。 还提供了胰腺来源的纤溶酶原激活物抑制剂多肽,载体,宿主细胞和用于制备它们的重组方法。 本发明还涉及用于治疗生理和病理疾病状况的方法,包括乳腺癌,以及用于检测病理障碍的诊断方法。

    Brain-associated inhibitor of tissue-type plasminogen activator
    65.
    发明授权
    Brain-associated inhibitor of tissue-type plasminogen activator 有权
    脑组织型纤溶酶原激活物抑制剂

    公开(公告)号:US06191260B1

    公开(公告)日:2001-02-20

    申请号:US09348817

    申请日:1999-07-08

    IPC分类号: C07K1481

    摘要: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human BAIT protein. BAIT polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders.

    摘要翻译: 本发明涉及一种新的BAIT蛋白,其是主要在脑组织中表达的丝氨酸蛋白酶超家族的成员。 特别地,提供编码人BAIT蛋白的分离的核酸分子。 还提供了BAIT多肽,载体,宿主细胞以及用于制备它们的重组方法。 本发明还涉及鉴定BAIT活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测神经系统相关疾病的诊断方法和用于治疗神经系统相关疾病的治疗方法。

    Purification of active and inactive/latent forms of plasminogen
activator inhibitor-1
    70.
    发明授权
    Purification of active and inactive/latent forms of plasminogen activator inhibitor-1 失效
    纯化纤溶酶原激活物抑制剂-1的活性和非活性/潜伏形式

    公开(公告)号:US5260419A

    公开(公告)日:1993-11-09

    申请号:US671433

    申请日:1991-03-20

    CPC分类号: C07K14/8132

    摘要: A method of separating active and inactive/latent forms of PAI-1 is disclosed comprising loading a sample containing a mixture of active and inactive/latent forms of PAI-1 to either an anion or cation exchange resin of 10-50 micron particle size and eluting active and inactive/latent forms of PAI-1 from the resin into separate fractions. Also disclosed is a method of extracting soluble E. coli-expressed recombinant PAI-1 from the lysed E. coli host cells in a buffered solution, wherein the ionic strength of the buffered solution is 8-25 millisiemens.

    摘要翻译: 公开了分离活性和非活性/潜伏形式的PAI-1的方法,其包括将含有活性和非活性/潜在形式的PAI-1的混合物的样品装载至10-50微米粒度的阴离子或阳离子交换树脂,以及 将PAI-1的活性和非活性/潜在形式从树脂洗脱成分离的级分。 还公开了在缓冲溶液中从裂解的大肠杆菌宿主细胞中提取可溶性大肠杆菌表达的重组PAI-1的方法,其中缓冲溶液的离子强度为8-25毫司。